Skip to main content
Equibles
NTRA logo

NTRA · Natera, Inc. · Investor Relations

Track NTRA — free

Use NTRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NTRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$412.50 -0.81 (-0.20%)
Russell 1000 member Rebalance outlook locked
Market Cap
$59.47B
Shares
144.14M
Volume · Sep 30 1.85M Avg daily vol (3M) 1.38M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-22 Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
2026-09-18 Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for Signatera™
2026-09-01 New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
2026-08-28 Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
2026-08-27 Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
2026-08-12 Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
2026-08-06 Natera Reports Second Quarter 2026 Financial Results
2026-08-05 Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
2026-07-30 Natera to Report its Second Quarter Results on August 6, 2026
2026-07-22 Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
2026-07-16 Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
2026-07-09 Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
2026-07-06 Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
2026-06-29 Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
2026-06-25 Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-24 Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
2026-06-23 NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
2026-06-18 Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
2026-06-04 Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
2026-06-03 Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
2026-05-29 Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
2026-05-28 Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
2026-05-26 Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
2026-05-21 Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
2026-05-21 Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

Past events

Date Event Type
2026-09-15 Baird 2026 Global Healthcare Conference Conference
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-08-12 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-06 Natera, Inc. Q2 Earnings Conference Call Earnings call
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-05-07 Natera, Inc. Q1 Earnings Conference Call Earnings call
2026-03-10 Leerink Partners Global Healthcare Conference 2026 Conference
2026-03-04 Raymond James 47th Annual Institutional Investors Conference Conference
2026-03-03 TD Cowen 46th Annual Health Care Conference Conference
2026-02-26 Natera, Inc. Q4 Earnings Conference Call Earnings call
2026-01-14 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-03 37th Annual Piper Sandler Healthcare Conference Conference
2025-11-19 Wolfe Research Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference in London Conference
2025-11-11 UBS Global Healthcare Conference Conference
2025-11-06 Natera, Inc. Q3 Earnings Conference Call Earnings call
2025-10-23 Natera Post-ESMO Investor Call Event
2025-09-23 Bernstein 2nd Annual Healthcare Forum Event
2025-09-09 Baird 2025 Global Healthcare Conference Conference
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference
2025-08-12 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-07 Natera, Inc. Q2 Earnings Conference Call Earnings call
2025-06-09 Goldman Sachs 46th Annual Global Healthcare Conference Conference
2025-05-21 2025 RBC Capital Markets Global Healthcare Conference Conference
2025-05-08 Natera, Inc. Q1 Earnings Conference Call Earnings call

Source: https://investor.natera.com/overview/default.aspx

Key facts CIK 1604821 CUSIP 632307104 13F (30d) 22 filings 16 filers Visit website Investor relations